We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Advanced Staining Solution to Accelerate Diagnostic Productivity for Mid-Sized and Large Labs

By LabMedica International staff writers
Posted on 20 Apr 2023
Print article
Image: Powered by Universal Access, BOND-PRIME enables labs to seamlessly adapt to any incoming workflows (Photo courtesy of Leica)
Image: Powered by Universal Access, BOND-PRIME enables labs to seamlessly adapt to any incoming workflows (Photo courtesy of Leica)

A more advanced and faster staining solution enables single or STAT slides to be processed in just one hour, allowing pathologists to quickly provide diagnoses, which is crucial for patients requiring urgent diagnostic decisions. This solution reduces the average turnaround time (TAT) for immunohistochemistry (IHC) slides to approximately 90 minutes and ensures 100% instrument utilization without constant supervision.

Leica Biosystems (Nussloch, Germany) has announced the European launch of the BOND-PRIME advanced staining solution, which seamlessly adapts and optimizes workflow to stain slides as required, without leaving any slide staining position unused. It features 70 open-access reagent positions and a total on-board capacity of 72 slides. Besides its adaptability and speed, the platform incorporates innovative technology to further improve the staining quality available to laboratories. This results in consistently sharp, clean stains that are gentle on sample tissue and exhibit minimal carry-over. Leica has introduced Active Reagent Control (ARC) to enable highly controlled reagent application and incubation. BOND-PRIME is now accessible for in vitro diagnostic use in specific countries within the EMEA regions, as well as the United States, Canada, Australia, and New Zealand.

“In today’s fast-paced healthcare environment, adaptability is essential to ensure that slides are processed in a timely manner, without compromising on quality,” explained Colin White, Senior Vice President of Advanced Staining, and Imaging. “BOND-PRIME is a generation ahead. It enables labs to achieve a high-speed, continuous workflow, an average single slide TAT of 90 minutes, no downtime and minimal need for manual intervention. The impact on quality and productivity is truly impressive.”

“We have a history of innovation that addresses specific customer needs,” said Gustavo Perez-Fernandez, President at Leica Biosystems. “The BOND-PRIME staining solution presents a quantifiable benefit to mid-sized and large laboratories in terms of both quality and greater efficiency. STAT cases can be processed quickly and efficiently, without holding back the validation of more routine cases. By streamlining workflow, the use of BOND-PRIME ensures that fewer cases overall are left pending.”

Related Links:
Leica Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.